BTIG Research set a $56.00 price objective on Eidos Therapeutics (NASDAQ:EIDX) in a research report report published on Friday morning, The Fly reports. The brokerage currently has a buy rating on the stock.

EIDX has been the subject of a number of other research reports. BMO Capital Markets lifted their price target on Eidos Therapeutics to $50.00 and gave the company an outperform rating in a research report on Monday, July 22nd. Zacks Investment Research upgraded Eidos Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 23rd. Finally, Piper Jaffray Companies started coverage on Eidos Therapeutics in a research report on Monday, July 22nd. They set an overweight rating and a $55.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $37.57.

EIDX stock opened at $45.97 on Friday. The company has a quick ratio of 20.89, a current ratio of 20.89 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.68 billion, a PE ratio of -24.72 and a beta of -0.99. Eidos Therapeutics has a twelve month low of $8.89 and a twelve month high of $47.58. The stock has a 50-day simple moving average of $39.41 and a two-hundred day simple moving average of $30.34.

Eidos Therapeutics (NASDAQ:EIDX) last posted its earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.01). On average, equities research analysts anticipate that Eidos Therapeutics will post -1.7 EPS for the current fiscal year.

In related news, insider Uma Sinha sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $36.13, for a total value of $180,650.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bridgebio Pharma, Inc. bought 882,353 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was purchased at an average price of $29.90 per share, with a total value of $26,382,354.70. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 30,000 shares of company stock valued at $1,171,700. Corporate insiders own 70.10% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Paloma Partners Management Co bought a new stake in Eidos Therapeutics in the 2nd quarter worth approximately $758,000. Bank of America Corp DE lifted its position in Eidos Therapeutics by 1,868.6% in the 2nd quarter. Bank of America Corp DE now owns 65,888 shares of the company’s stock worth $2,047,000 after buying an additional 62,541 shares during the last quarter. Cormorant Asset Management LP lifted its position in Eidos Therapeutics by 8.7% in the 2nd quarter. Cormorant Asset Management LP now owns 551,921 shares of the company’s stock worth $17,154,000 after buying an additional 44,357 shares during the last quarter. Invesco Ltd. lifted its position in Eidos Therapeutics by 3.1% in the 2nd quarter. Invesco Ltd. now owns 46,273 shares of the company’s stock worth $1,438,000 after buying an additional 1,383 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in Eidos Therapeutics by 3.3% in the 2nd quarter. Vanguard Group Inc. now owns 376,178 shares of the company’s stock worth $11,692,000 after buying an additional 11,857 shares during the last quarter. Institutional investors own 32.46% of the company’s stock.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Recommended Story: Municipal Bonds

The Fly

Analyst Recommendations for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.